Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) PT at $81.73

Shares of CG Oncology, Inc. (NASDAQ:CGON) have earned an average rating of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $81.7273.

Several analysts have recently commented on the stock. Wedbush lifted their price target on shares of CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a research report on Monday, May 18th. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Royal Bank Of Canada raised their target price on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th.

Insider Activity at CG Oncology

In related news, Director Brian Guan-Chyun Liu acquired 371,085 shares of CG Oncology stock in a transaction that occurred on Thursday, June 25th. The shares were purchased at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the acquisition, the director owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director James Mulay sold 1,964 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $60.12, for a total transaction of $118,075.68. Following the transaction, the director directly owned 654 shares of the company’s stock, valued at approximately $39,318.48. This trade represents a 75.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 28,564 shares of company stock worth $1,986,532. Company insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

Several institutional investors have recently added to or reduced their stakes in CGON. Wellington Management Group LLP raised its position in CG Oncology by 190.3% in the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock valued at $222,055,000 after purchasing an additional 3,613,885 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock worth $142,961,000 after buying an additional 1,854,386 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of CG Oncology in the fourth quarter valued at $62,909,000. Bank of America Corp DE raised its holdings in shares of CG Oncology by 409.9% in the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after buying an additional 1,396,170 shares during the period. Finally, State Street Corp raised its holdings in shares of CG Oncology by 46.4% in the 4th quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after buying an additional 950,028 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Price Performance

Shares of CG Oncology stock opened at $73.32 on Friday. The stock has a market capitalization of $6.47 billion, a P/E ratio of -31.47 and a beta of 0.22. The business has a 50 day simple moving average of $64.71 and a two-hundred day simple moving average of $60.08. CG Oncology has a 12 month low of $23.65 and a 12 month high of $77.00.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. As a group, research analysts anticipate that CG Oncology will post -2.89 EPS for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.